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Randomized controlled trials are the primary source of
evidence for assessing the effectiveness of cancer screen-
ing. Thus far, trial data have mainly been analyzed using
relative risk estimates or proportional hazard models [1].
Proportional hazard models assume that screening results
in a time-independent reduction in cancer mortality. Han-
ley, Liu and coworkers have developed a model with a
time-dependent mortality reduction, see elsewhere in this
issue of the journal [2, 3]. The model assumes that the
reduction in mortality from the target cancer appears after a
delay following a screen, and eventually disappears. Mor-
tality reductions from subsequent screening rounds are
superimposed. The resulting function has a bathtub form,
and is determined by two parameters: the time between a
screen and maximum relative mortality reduction, and the
value of the maximum relative mortality reduction [2]. The
authors have applied their method to data from prostate
cancer [1], lung cancer [3], colorectal cancer [3] and breast
cancer [2], using excellent graphical illustrations (Fig-
ures 3 and 4 in [3]).
The Hanley–Liu model is more realistic than the pro-
portional hazard model. In practice, discriminating
between the two models can be difficult. Designers of
screening trials are aware of the bathtub dynamics of
mortality reduction. They mitigate the influence of the
initial phase of (near) absence of reduction by excluding
persons with an already established diagnosis of the target
cancer. A good compromise follow-up duration is the crux
for dealing with the tapering off phase at the end. Follow-
up should neither be too short when mortality reduction is
still increasing nor too long with much noise from deaths
which could not have been prevented by screening anyhow.
With these choices, most cancer deaths in screening trials
will occur in the bottom part of the bathtub, where the
constant mortality reduction of the proportional hazard
model is a good approximation to the Hanley–Liu model.
And indeed, it proved not to be possible to discriminate
between the two models in the analysis of the Danish breast
cancer data [2]. The scatter of the time-dependent relative
mortality dots in Figures 3 and 4 in [3] suggests that this
might also be the case for the lung cancer and colorectal
cancer analyses. This lack of discrimination with more
complex models might be a reason why the simple pro-
portional hazard model has persisted as the model of choice
for statistical analysis of trial data.
The time-dependent mortality reduction curve of the
Hanley–Liu model allows us to reflect on trial design issues
like screening interval, follow-up time and power analysis.
In order to provide maximal information, the interval
between subsequent screenings should be sufficiently long
to provide information about the whole trajectory of the
bathtub mortality reduction curve. A trial with 3-year
intervals will be more informative than a trial with 1-year
intervals.
Contrary to the proportional hazard model, duration of
follow-up is not crucial for the Hanley–Liu model. While
mortality after long follow-up is a source of random noise
in the proportional hazard model, it is informative in the
Hanley–Liu model for estimating the dynamics of the
mortality reduction.
The high costs of screening trials strongly depend on
their size. Because of the use of the time-dimension of the
mortality data, power calculations will undoubtedly lead to
a smaller sample size for the Hanley–Liu model than for
the proportional hazard model.
Hanley and Liu note that use of their model is hindered
by sparse data. This problem would even become worse
when important determinants like age at first invitation and
rank of the screening round would be included in the model
[2]. The appeal of Hanley and Liu to screening data owners
to collaborate is therefore timely and should be endorsed.
In addition, it could be recommended that Lexis diagrams
as used by Hanley and Liu, with number of deaths and
person years at risk in each cell [2] should routinely be
included in reports of screening trial results. The Lexis
diagram has an age- and a calendar-time axis, describes
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how cohorts progress along these axes and constitutes a
database for further epidemiologic analysis [4].
Mortality analysis of screening trials usually takes place
between 15 and 30 years after start of the trial. During this
period, some of the biological and behavioral processes
which underlie the mortality effects of cancer screening
will have changed. Underlying processes which can change
over time include incidence of cancer, the stage distribu-
tion of diagnosed cancers in the absence of screening, the
stage-specific survival of cancer with current treatment, the
sensitivity and specificity of screening tests in different
disease stages, compliance to the screening, the charac-
teristics of further diagnostics in case of an abnormal
screening test result, and the stage specific survival in
screen detected cancers, including precursor lesions. For
example participants in the Minnesota trial for colorectal
cancer screening were (healthy) volunteers, and since the
trial the FOBT has largely been replaced by quantitative
immunochemical blood tests and new cancer treatments
have become available. The proportional hazards and
Hanley–Liu models can both be characterized as modeling
the mortality response to a screening stimulus which is
delivered in the context of underlying processes. The
models have no mechanism for correcting the response for
secular changes in the underlying processes. This is a major
problem for using the results of a statistical analysis
beyond the trial context, for example for guideline
development.
Many beneficial and harmful outcomes have to be taken
into account when comparing screening policies, including
overtreatment, anxiety after positive screening tests and
complications from screening, follow-up tests and treat-
ment. See [5] for a table of outcomes for colorectal cancer
screening. Only one of the outcomes, mortality, is
addressed by the proportional hazards and Hanley–Liu
models. Mortality is arguable the most important outcome,
as cancer screening without mortality reduction is useless.
The mortality output of the Hanley–Liu model which
consists of the curve of relative mortality between
screening and control group has to be processed before it
can be used in decision making. A switch has to be made
from relative to absolute mortality, in order to avoid that
high and low cancer incidence situations would be treated
the same. Age of death should be taken into account by
calculating the expected number of life-years gained when
preventing a death. Otherwise, prevented deaths at age 50
and age 90 would be valued the same. Two further possible
actions are adjustment for time-preference by putting more
weight on nearby compared to far away life-years, and
adjustment for quality of life by calculating quality-ad-
justed life years [6].
The suggestion that the Hanley–Liu model can be used
for deriving optimal ages and frequency of screening [2] is
rather optimistic in view of the need to correct for secular
changes and to weigh many harms and benefits. It might be
better to turn to mathematical models which are developed
with their use for decision making in mind. These so-called
decision analytic models consider demography, epidemi-
ology, natural history, screening tests, treatment and other
processes, and aim to integrate available data to estimate
the health consequences of alternative screening strategies
[7]. By now, decision analytic models have been developed
in many fields of medicine. For cancer screening, a large
number of model groups collaborate in the Cancer Inter-
vention and Surveillance Modeling Network (CISNET).
The models have been described in a standardized way, see
https://cisnet.cancer.gov/resources/profiles.html. Decision
analytic models are increasingly used for informing
screening guidelines development, for example by the
United States Preventive Services Task Force [8, 9].
The scientific status of decision analytic models is
unclear. While statistical models are developed within the
firm context of probability theory and theoretical statistics
[3], relevance is the primary concern in the development of
decision analytic models. In order to increase their trust-
worthiness, general recommendations for good research
practice in decision analytic modeling have been formu-
lated [7]. For cancer screening, model quality and rele-
vance have been discussed in [10]. The quality and
credibility of decision models strongly depends on their
performance in reproducing results of screening studies.
They are considered most useful in situations where strong
primary data are available [10]. For example, parameters of
a decision analytic model for colorectal cancer screening
could be fitted to the results of three randomized trials [11].
In view of the complexity of decision analytic models,
much can be gained from collaboration between modeling
groups [12] and from multi-model studies [13].
In conclusion, statistical models and decision analytic
models are both important in cancer screening. Statistical
models are essential for analysis of trial data. Decision
analytic models are used in screening guidelines develop-
ment. Decision modelers can learn from statistical models
for improving the fitting and validation of primary data.
Statistical modelers can learn from decision analytic
models for improving the usefulness of their models for
decision making. Hanley and Liu have improved on
existing statistical models. By modeling the time dimen-
sion of the mortality reduction they improved the relevance
for decision making, especially with regard to the question
of optimal screening intervals. Decision analytic modelers
should in turn try to learn from the Hanley–Liu model for
improving the ways in which they fit their model to pri-
mary data.
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